Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors
Company Raised $112 Million to Date and is on Track to Generate Initial Clinical Data by Year End BURLINGTON, Mass.–(BUSINESS WIRE)–Lifordi Immunotherapeutics, Inc., a clinical-stage biotech company developing antibody-drug conjugates (ADCs) for the treatment of…